- Details
- Ashish Kamat and Patrick Soon-Shiong explore the clinical development and FDA approval of Anktiva for bladder cancer. Dr. Soon-Shiong outlines the journey from initial studies in BCG-naive and BCG-unresponsive patients to approval. Anktiva, combined with BCG, shows high complete remission rates and prolonged duration of response, providing a significant advancement in bladder preservation. Dr. Soo...
|
- Details
- Ashish Kamat interviews Patrick Soon-Shiong about the approval of Anktiva for bladder cancer treatment. Dr. Soon-Shiong shares his journey from pancreatic surgery at UCLA to developing this innovative therapy. He emphasizes the need to activate the immune system, particularly natural killer (NK) cells, which play a crucial role in targeting cancer cells. Anktiva, an IL-15 based therapy, works syne...
|
- Details
- Ashish Kamat and Yair Lotan discuss an innovative AI-based assessment tool presented by Valar Labs, aimed at refining the management of BCG-unresponsive bladder cancer. Dr. Lotan discusses the tool's capability to enhance the precision of prognosis and treatment strategies by analyzing pathologic slides with AI to identify high-risk patients who might not respond well to BCG treatment. This AI alg...
|
- Details
- Zach Klaassen hosts Stephen B Williams to discuss an innovative AI biomarker for non-muscle invasive bladder cancer. Dr. Williams emphasizes the significance of refining clinical predictors for bladder cancer, highlighting the potential of the AI biomarker to revolutionize treatment approaches. This tool, developed by Valar Labs using data from over 300,000 specimens, aids in distinguishing betwee...
|
- Details
- Zachary Klaassen discusses the future of bladder cancer treatment with Mark Tyson. They explore the challenges of sequencing treatments for non-muscle invasive bladder cancer, particularly in BCG-naive and unresponsive patients. Dr. Tyson emphasizes the evolving landscape with multiple emerging drugs like Adstiladrin and N-803, which recently received FDA approval. They examine the difficulty in d...
|
- Details
- Sam Chang engages with Ashish Kamat to discuss integrating Adstiladrin into regular clinical practice. During their conversation, Dr. Kamat elaborates on Adstiladrin's journey from clinical trials to its current commercial use, highlighting its 53% complete response rate. They explore the challenges and decisions involved in choosing treatments for BCG-unresponsive non-muscle invasive bladder canc...
|
- Details
- Ashish Kamat introduces Stephen B. Williams who discusses findings from his study on blue light cystoscopy in bladder cancer treatment, conducted within the VA healthcare system. The study utilized a propensity score-matched analysis to compare the outcomes of blue light versus white light cystoscopy, focusing on bladder cancer recurrence, progression, and overall survival. The analysis revealed s...
|
- Details
- Ashish Kamat hosts Sam Chang to discuss the SunRISe-3 trial. Dr. Chang presents the ongoing trial investigating the efficacy of TAR-200, either alone or combined with cetrelimab, against BCG in treating patients with BCG-naive bladder cancer. TAR-200, a targeted release system using gemcitabine, is tested for its potential benefits over traditional treatments due to its unique delivery system aime...
|
- Details
- Ashish Kamat introduces Jeffrey Holzbeierlein, who discusses the recent updates to the American Urological Association's (AUA) guidelines for managing non-muscle invasive bladder cancer. Published in partnership with the Society for Urologic Oncology, these evidence-based guidelines highlight key changes from the 2016 and 2017 versions. The updates include the management of variant histologies, re...
|
- Details
- Sam Chang introduces a dialogue with John Gore and Angie Smith, who are leading a trial named CISTO, aimed at addressing treatment decisions in non-muscle invasive bladder cancer. The trial compares the efficacy of intravesical therapy and surgery in patients with recurrent bladder cancer who have previously undergone BCG treatment. Emphasizing a pragmatic approach, the trial notably includes phys...
|
